Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)
整个生命周期精神分裂症的优化和个性化干预措施 (OPAL)
基本信息
- 批准号:10623751
- 负责人:
- 金额:$ 209.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdolescenceAdvocateAffectAreaAssertivenessAssessment toolAttentionBlack, Indigenous, People of ColorCaringCessation of lifeClinicClinicalClinical ResearchCognitionCognitiveCommunicationCommunitiesDataDementiaDevelopmentDiagnosisDiseaseEffectivenessEnsureEuropeFormulationFosteringGoalsHealthHealth TechnologyHomelessnessImpairmentIndividualInequityInfrastructureInterventionInterviewLongevityMeasurementMental HealthMethodologyMethodsMobile Health ApplicationNamesNew YorkOccupationalOutcomeParticipantPersonsPharmaceutical PreparationsPilot ProjectsPolicy MakerPremature MortalityProcessQualitative MethodsRecommendationRegimenResearch PersonnelResearch SupportResource AllocationResourcesRiskSafetySchizophreniaScientistServicesStrategic PlanningTarget PopulationsTestingTrainingTranslational ResearchTreatment EffectivenessUnited States Centers for Medicare and Medicaid ServicesWorkclinical translationcompare effectivenessdementia riskdisabilitydisability riskeffective interventionemerging adultend of lifeethnoracialevidence baseexperiencefeasibility testingfirst episode psychosisflexibilityhealth disparityimprovedindividualized medicineinnovationinterdisciplinary collaborationmHealthmood symptomnovelpeople of colorpersistent symptomperson centeredpersonalized interventionpersonalized medicinepractice settingprematurepsychotic symptomsreduce symptomsroutine practicesatisfactionservice deliveryshared decision makingside effectskillssocialsocial health determinantstooltraining opportunitytreatment optimizationtreatment strategy
项目摘要
The OPAL Center is named after its goal of Optimizing and Personalizing interventions for people with
schizophrenia Across the Lifespan. The target population for this ALACRITY Center is people diagnosed with
schizophrenia, which typically affects individuals from adolescence or early adulthood until the end of life.
Affected individuals commonly have impaired social and occupational functioning; experience persistent
psychotic and mood symptoms; have cognitive problems that may progress; and are at risk for disability and
premature death. Black, Indigenous, and People of Color (BIPOC) individuals are particularly at risk of poor
outcomes. The goal of this renewal application is to extend our efforts to accelerate the development and
implementation of effective, individualized treatments for schizophrenia in real clinical settings.
The specific aims of the Center renewal application are as follows:
1. Strengthen our infrastructure that supports research that examines innovative ways to optimize
treatments for people with schizophrenia throughout the lifespan and that accelerates the translation of clinical
research on schizophrenia to routine practice settings.
2. Conduct projects that develop, adapt, and test innovative, accessible, and person-centered interventions
that improve engagement in treatment and can be readily deployed.
3. Train scientists who will conduct translational research on interventions for schizophrenia.
The OPAL Signature Project will use 16 years of data (2007-2022) from the Center for Medicaid and
Medicare Services (CMS) to test hypotheses about risk factors for dementia among people diagnosed with
schizophrenia and compare the effectiveness of treatment strategies after diagnosis of dementia. We will then
integrate our findings to adapt a Cognitive Health Toolkit that provides assessment and management tools.
Exploratory Project 1 tests a novel, person-centered approach to assessment and treatment initiation
for BIPOC individuals with psychotic symptoms in community mental health clinics that incorporates an
adapted version of the Cultural Formulation Interview to improve diagnosis and treatment engagement.
Exploratory Project 2 will build on work done in Europe to adapt and test the feasibility and
preliminary effectiveness of Flexible Assertive Community Treatment (ACT), which will allow ACT teams to
allocate resources according to the individual needs of participants, improving efficiency and outcomes.
Exploratory Project 3 uses mobile health (mHealth) technology to deliver measurement-based care
and improve the person-centered outcomes of individuals with schizophrenia across the lifespan.
OPAL projects use the Center's common resources and methodologies to improve implementation and
personalization of treatments for important problems. Stakeholders help us to refine and adapt interventions for
effective implementation in real-world settings.
OPAL 中心以其为患有以下疾病的人优化和个性化干预措施的目标而命名
精神分裂症贯穿整个生命周期。该 ALACRITY 中心的目标人群是被诊断患有以下疾病的人
精神分裂症,通常影响从青春期或成年早期直至生命终结的个体。
受影响的个人通常有社会和职业功能受损;经验持久
精神病和情绪症状;存在可能进展的认知问题;并面临残疾风险
过早死亡。黑人、原住民和有色人种 (BIPOC) 个体尤其面临贫困风险
结果。此续订申请的目标是扩大我们的努力,加速开发和
在真实的临床环境中对精神分裂症实施有效的个体化治疗。
中心续展申请的具体目的如下:
1. 加强我们的基础设施,支持研究优化创新方法
对精神分裂症患者进行终生治疗,并加速临床转化
将精神分裂症研究纳入常规实践环境。
2. 开展开发、调整和测试创新、易于使用且以人为本的干预措施的项目
提高治疗参与度并且易于部署。
3. 培训科学家进行精神分裂症干预措施的转化研究。
OPAL 签名项目将使用医疗补助中心 16 年(2007 年至 2022 年)的数据和
医疗保险服务 (CMS) 将在诊断为痴呆症的人群中测试有关痴呆症危险因素的假设
精神分裂症并比较痴呆症诊断后治疗策略的有效性。我们随后将
整合我们的研究结果以适应提供评估和管理工具的认知健康工具包。
探索性项目 1 测试了一种新颖的、以人为本的评估和治疗启动方法
为社区心理健康诊所中患有精神病症状的 BIPOC 个人提供服务,其中包括
文化公式访谈的改编版本,以提高诊断和治疗的参与度。
探索性项目 2 将建立在欧洲所做的工作的基础上,以适应和测试可行性和
灵活自信社区治疗 (ACT) 的初步效果,这将使 ACT 团队能够
根据参与者的个人需求分配资源,提高效率和成果。
探索性项目 3 使用移动医疗 (mHealth) 技术提供基于测量的护理
并改善精神分裂症患者一生中以人为本的结果。
OPAL 项目使用中心的共同资源和方法来改进实施和
对重要问题进行个性化治疗。利益相关者帮助我们完善和调整干预措施
在现实环境中有效实施。
项目成果
期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Feasibility and Utility of Different Approaches to Violence Risk Assessment for Young Adults Receiving Treatment for Early Psychosis.
- DOI:10.1007/s10597-021-00922-6
- 发表时间:2022-08
- 期刊:
- 影响因子:2.7
- 作者:Rolin SA;Scodes J;Dambreville R;Nossel IR;Bello I;Wall MM;Scott Stroup T;Dixon LB;Appelbaum PS
- 通讯作者:Appelbaum PS
The Effectiveness of Discharge Planning for Psychiatric Inpatients With Varying Levels of Preadmission Engagement in Care.
- DOI:10.1176/appi.ps.202000863
- 发表时间:2022-02-01
- 期刊:
- 影响因子:0
- 作者:Smith TE;Haselden M;Corbeil T;Wall MM;Tang F;Essock SM;Frimpong E;Goldman ML;Mascayano F;Radigan M;Schneider M;Wang R;Rodgers I;Dixon LB;Olfson M
- 通讯作者:Olfson M
Assessing metamotivation in schizophrenia: A pilot study of the Brief Regulation of Motivation Scale (BRoMS).
- DOI:10.1016/j.psychres.2022.114799
- 发表时间:2022-11
- 期刊:
- 影响因子:11.3
- 作者:Lynch, David A.;Brown, Marie;Saperstein, Alice;Stefancic, Ana;Medalia, Alice
- 通讯作者:Medalia, Alice
Metamotivation in people diagnosed with schizophrenia: A conceptual introduction and qualitative study.
- DOI:10.1016/j.schres.2021.06.003
- 发表时间:2022-05
- 期刊:
- 影响因子:4.5
- 作者:Hansen, Marie C.;Lynch, David A.;Stefancic, Ana;Medalia, Alice
- 通讯作者:Medalia, Alice
Predicting response to cognitive training for schizophrenia using results from two studies with different outcomes.
- DOI:10.1016/j.schres.2021.03.006
- 发表时间:2021-05
- 期刊:
- 影响因子:4.5
- 作者:Saperstein AM;Choi CJ;Jahshan C;Lynch DA;Wall M;Green MF;Medalia A
- 通讯作者:Medalia A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS SCOTT STROUP其他文献
THOMAS SCOTT STROUP的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS SCOTT STROUP', 18)}}的其他基金
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
2/2-A 治疗精神分裂症的长效注射药物的比较 -ACLAIMS
- 批准号:
8018897 - 财政年份:2009
- 资助金额:
$ 209.08万 - 项目类别:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
2/2-A 治疗精神分裂症的长效注射药物的比较 -ACLAIMS
- 批准号:
8323933 - 财政年份:2009
- 资助金额:
$ 209.08万 - 项目类别:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
2/2-A 治疗精神分裂症的长效注射药物的比较 -ACLAIMS
- 批准号:
7882587 - 财政年份:2009
- 资助金额:
$ 209.08万 - 项目类别:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
2/2-A 治疗精神分裂症的长效注射药物的比较 -ACLAIMS
- 批准号:
8132232 - 财政年份:2009
- 资助金额:
$ 209.08万 - 项目类别:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
2/2-A 治疗精神分裂症的长效注射药物的比较 -ACLAIMS
- 批准号:
8465272 - 财政年份:2009
- 资助金额:
$ 209.08万 - 项目类别:
CLINICAL MANAGEMENT OF METABOLIC PROBLEMS IN PATIENTS WITH SCHIZOPHRENIA:SW
精神分裂症患者代谢问题的临床管理:SW
- 批准号:
7716895 - 财政年份:2008
- 资助金额:
$ 209.08万 - 项目类别:
Addressing Challenges in Schizophrenia Research
应对精神分裂症研究的挑战
- 批准号:
6788858 - 财政年份:2003
- 资助金额:
$ 209.08万 - 项目类别:
Addressing Challenges in Schizophrenia Research
应对精神分裂症研究的挑战
- 批准号:
7258786 - 财政年份:2003
- 资助金额:
$ 209.08万 - 项目类别:
Addressing Challenges in Schizophrenia Research
应对精神分裂症研究的挑战
- 批准号:
7104210 - 财政年份:2003
- 资助金额:
$ 209.08万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 209.08万 - 项目类别:
Research Grant














{{item.name}}会员




